Company profile

Axsome Therapeutics

AXSM · NASDAQ · USA

Share price · AXSM

$215.69-11.71 (-5.15%) 3M

close as of 2026-08-18 · 24h delayed · vol 469K

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(3 total)
3Total Assets
1Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Dextromethorphan/bupropion(Auvelity)
Approved
sigma-1/NMDASmall molecule
Alzheimer's DiseaseMajor Depressive Disorder
Balipodect (TAK-063)No recent activity
Phase 3
Phosphodiesterase 10A (PDE10A)Small molecule
Schizophrenia
Solriamfetol(Sunosi)
Phase 3
Dopamine/norepinephrine transporterSmall molecule
Major Depressive Disorder

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.